医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Jinchi Biotech Ltd. intends to list on the National Stock Exchange of Australia (NSX) and subsequently in Germany

2014年03月19日 AM03:00
このエントリーをはてなブックマークに追加


 

ZHANGJIAJIE, China

Jinchi Biotech Ltd., a biotechnology company based in Zhangjiajie, Hunan Province, today announced that they intend to list on the National Stock Exchange of Australia, followed by a subsequent secondary listing on the Frankfurt Stock Exchange. Jinchi has engaged London Capital Associates to assist in preparing the company’s registration for the NSX exchange, and expects to have their registration statements submitted soon.

Jinchi Biotech owns and runs the world’s one and only Giant Salamander Science Museum, which also serves as the company’s research base. Located in the world famous tourist destination Zhangjiajie, the museum attracts nearly 150,000 tourists each year from over the world. With a strong international scientific research team, Jinchi Biotech Inc. has established a Sino-Russian Strategic Alliance, conducted extensive experiments, published 19 academic papers, obtained 5 core patents, and many more rewards and certificates.

Jinchi always takes innovation and development of products seriously. Through years of research and development, Jinchi has discovered exclusive patent ingredient Giant Salamander Glycopeptides (ADGPs) from giant salamander slime and created a unique anti-aging solution that combines skincare products and intake supplements. Jinchi’s two product lines, namely Shinique and Andrias, with products including food products, skincare products and toothpaste, etc. are designed and developed based on Traditional Chinese Medicine theory, GMPC and ISO 22716:2007 certified, clinical tested, and popular among consumers. Jinchi has a development strategy that can benefit investor in different time horizons. In the short run, Jinchi will focus on skincare products, eventually Jinchi will focus on both skincare and biomedicine products in the long run.

ABOUT JINCHI

www.jc-biotech.com

Jinchi Biotech Ltd. is an ecology oriented biotech company, which is dedicated to R&D and application of bio-technology, and adopts circular economy business model. Founded in 2009, Jinchi built the world’s one and only Giant Salamander Museum, which was approved by the national government as a key Science Education Base. Jinchi has established long-term cooperation with a great number of colleges and universities, scientific research institutions, and clinical research centers, built the central laboratory, and obtained 4 national patents, which has laid a solid foundation for Jinchi’s continuing development in biomedical and health industries. Jinchi is mainly specialized in the R&D of giant salamander related bio-technology products, with more than 50 skincare and health products produced in two product lines, namely Shinique and Andrias. Jinchi has gradually formed its comprehensive business model, with the Giant Salamander Museum as a platform, E-commerce as a channel, accompanied by specialized market, boutique shops and flagship store. Devoting to the health industry, Jinchi values virtue and goodwill, and commits to deliver quality products to consumers.

Disclaimer

The statements contained herein are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements.

CONTACT

JINCHI
Chan Luo, 86-731-8979-2661
ir@jc-biotech.com

同じカテゴリーの記事 

  • ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
  • PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA
  • AriBio 获得欧洲药品管理局对AR1001治疗阿尔茨海默病3期临床试验(POLARIS-AD)的授权
  • AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)
  • ReNAgadeセラピューティクス、GanNA Bioと糖鎖生物学に対するコミットメントを継続